CalciMedica Reports Q2 2026 Results: $18.6M Cash, Runway into 2H 2027; FDA Aligns on Phase 2b AP Trial Design

summarizeSummary

CalciMedica reported Q2 2026 results with $18.6M cash and runway into 2H 2027, FDA alignment on its Phase 2b AP trial design, and mid-2027 catalysts for its pulmonary hypertension programs.

check_boxKey Events · Earnings and Guidance · CALC

• Q2 2026 Financial Results

  Net loss of $7.7M ($0.45/share) on reduced R&D and G&A spending; cash and equivalents of $18.6M as of June 30, 2026, expected to fund operations into the second half of 2027.

• FDA Alignment on Phase 2b AP Trial

  FDA agreed that the primary endpoint for the Phase 2b acute pancreatitis trial will measure whether Auxora can reduce new-onset severe respiratory failure, with key secondary endpoints including multi-organ failure and time to medical readiness for discharge.

• Pulmonary Hypertension Catalysts Set for Mid-2027

  Auxora Phase 1b proof-of-concept data in PAH and the CM5480 IND submission are both anticipated in mid-2027, representing the next major clinical milestones.

• Cash Runway Extension

  The $18.6M cash position, bolstered by the recent private placement, extends the runway into the second half of 2027, covering the anticipated mid-2027 data readouts.

auto_awesomeAnalysis · CALC · Life Sciences

CalciMedica disclosed Q2 2026 financials with a net loss of $7.7 million and $18.6 million in cash, providing runway into the second half of 2027. The company also announced FDA alignment on the Phase 2b acute pancreatitis trial primary endpoint — new-onset severe respiratory failure — and set mid-2027 timelines for Auxora PAH data and the CM5480 IND submission. These updates come against a backdrop of recent financing and a pending reverse stock split vote, making the clinical and cash runway clarity material for a micro-cap biotech.